Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis "AbbVie's first-quarter results were well ahead of our expectations and reflect ...

These five Dividend Aristocrats have the least negligible impact from the tariffs and are ideal for passive income investors.

Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Four healthcare dividend stocks with significant upside potential and safe dividends look like outstanding investing ideas ...

(Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of ...

Pharmaceutical giant AbbVie issued a new slate of challenges this week against states with laws requiring drugmakers to offer discounted medications to an unlimited number of contract pharmacies.

自 2023 年 11 月以来，AbbVie(NYSE : ABBV) 的股价上涨了 16%，而标准普尔 500 指数的回报率为 9.41%。在 AbbVie 以 100 亿美元收购癌症开发商 ImmunoGen 之后 ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

Wednesday's jaw-dropping stock-market rally on President Donald Trump's surprising tariff reversal is one for the history books. The S&P 500 skyrocketed 9.52% in a kneejerk reaction to Trump's ...

Keith Speights has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.